View : 582 Download: 163

Increased serum levels of mutant p53 proteins in patients with colorectal cancer

Title
Increased serum levels of mutant p53 proteins in patients with colorectal cancer
Authors
Shim K.-S.Kim K.-H.Park B.-W.Lee S.-Y.Choi J.-H.Han W.-S.Park E.-B.
Ewha Authors
한운섭박응범김광호이선영
SCOPUS Author ID
한운섭scopusscopus; 박응범scopus; 김광호scopus; 이선영scopusscopus
Issue Date
1998
Journal Title
Journal of Korean Medical Science
ISSN
1011-8934JCR Link
Citation
Journal of Korean Medical Science vol. 13, no. 1, pp. 44 - 48
Indexed
SCI; SCIE; SCOPUS; KCI scopus
Document Type
Article
Abstract
We have examined the serum levels of the mutant p53 protein in patients with colorectal cancer preoperatively (n=50), and in patients with adenomatous polyp (n=13). Mutant p53 protein in patients after curative surgical resection of colorectal cancer (n=26, part of the fifty preoperative patients) was also measured. Serum samples were stored frozen at -70°C until the time of analysis. We used the p53 mutant ELISA (QIA03, CALBIOCHEM) system. Serum levels of the mutant p53 protein in patients with colorectal cancer (mean=0.97±0.14 ng/ml, ranged from 0.7 ng/ml to 1.37 ng/ml, n=50) were significantly greater than those in patients with adenomatous polyp (mean=0.73±0.06 ng/ml, ranged from 0.69 ng/ml to 0.83 ng/ml) (p<0.001). There was a significant correlation between serum p53 levels and CA19-9 levels (p<0.01). Serum levels of the mutant p53 protein prior to surgery (mean=0.97±0.13 ng/ml, n=26) significantly decreased after surgical resection of tumor (mean=0.82±0.07 ng/ml) (p<0.001, paired t-test). These results suggest that mutant p53 protein might be used as a potential biomarker in the management of patients with colorectal cancer. Further study is warranted to establish its clinical significance. Copyright © The Korean Academy of Medical Sciences.
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
Increased serum levels.pdf(648.56 kB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE